AZN
Income statement / Annual
Last year (2025), Astrazeneca plc's total revenue was $58.74 B,
an increase of 8.63% from the previous year.
In 2025, Astrazeneca plc's net income was $10.26 B.
See Astrazeneca plc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$58.74 B |
$54.07 B |
$45.81 B |
$44.35 B |
$37.42 B |
$26.62 B |
$24.38 B |
$22.09 B |
$22.47 B |
$23.00 B |
| Cost of Revenue |
$10.63 B
|
$10.21 B
|
$8.27 B
|
$12.39 B
|
$12.44 B
|
$5.30 B
|
$4.92 B
|
$4.94 B
|
$4.32 B
|
$4.13 B
|
| Gross Profit |
$48.11 B
|
$43.87 B
|
$37.54 B
|
$31.96 B
|
$24.98 B
|
$21.32 B
|
$19.46 B
|
$17.15 B
|
$18.15 B
|
$18.88 B
|
| Gross Profit Ratio |
0.82
|
0.81
|
0.82
|
0.72
|
0.67
|
0.8
|
0.8
|
0.78
|
0.81
|
0.82
|
| Research and Development Expenses |
$14.23 B
|
$13.58 B
|
$10.94 B
|
$9.76 B
|
$9.74 B
|
$5.99 B
|
$6.06 B
|
$5.93 B
|
$5.76 B
|
$5.89 B
|
| General & Administrative Expenses |
$19.93 B
|
$19.67 B
|
$17.68 B
|
$17.45 B
|
$15.14 B
|
$0.00
|
$0.00
|
$0.00
|
$10.23 B
|
$9.41 B
|
| Selling & Marketing Expenses |
$579.00 M
|
$555.00 M
|
$539.00 M
|
$536.00 M
|
$446.00 M
|
$11.90 B
|
$11.99 B
|
$10.98 B
|
$310.00 M
|
$326.00 M
|
| Selling, General & Administrative Expenses |
$20.51 B
|
$20.22 B
|
$18.22 B
|
$17.98 B
|
$15.59 B
|
$11.90 B
|
$11.99 B
|
$10.98 B
|
$10.54 B
|
$9.74 B
|
| Other Expenses |
-$381.00 M
|
$56.00 M
|
$193.00 M
|
$457.00 M
|
-$1.40 B
|
-$1.73 B
|
-$1.51 B
|
-$3.15 B
|
-$1.83 B
|
-$1.66 B
|
| Operating Expenses |
$34.36 B
|
$33.86 B
|
$29.35 B
|
$28.20 B
|
$23.92 B
|
$16.16 B
|
$16.54 B
|
$13.77 B
|
$14.47 B
|
$13.97 B
|
| Cost And Expenses |
$45.00 B
|
$44.07 B
|
$37.62 B
|
$40.59 B
|
$36.36 B
|
$21.46 B
|
$21.46 B
|
$18.70 B
|
$18.79 B
|
$18.10 B
|
| Interest Income |
$360.00 M
|
$345.00 M
|
$301.00 M
|
$81.00 M
|
$43.00 M
|
$83.00 M
|
$165.00 M
|
$138.00 M
|
$109.00 M
|
$59.00 M
|
| Interest Expense |
$1.69 B
|
$1.68 B
|
$1.59 B
|
$1.33 B
|
$1.28 B
|
$1.27 B
|
$1.40 B
|
$1.37 B
|
$1.36 B
|
$1.37 B
|
| Depreciation & Amortization |
$5.73 B
|
$5.07 B
|
$4.93 B
|
$5.25 B
|
$4.10 B
|
$2.90 B
|
$3.76 B
|
$3.75 B
|
$3.04 B
|
$2.36 B
|
| EBITDA |
$19.83 B |
$15.44 B |
$13.42 B |
$9.09 B |
$5.11 B |
$8.08 B |
$6.71 B |
$7.11 B |
$6.62 B |
$7.28 B |
| EBITDA Ratio |
0.34
|
0.29
|
0.29
|
0.2
|
0.14
|
0.3
|
0.28
|
0.32
|
0.29
|
0.32
|
| Operating Income Ratio |
0.23
|
0.18
|
0.18
|
0.08
|
0.03
|
0.19
|
0.12
|
0.15
|
0.16
|
0.21
|
| Total Other Income/Expenses Net |
-$1.34 B
|
-$1.31 B
|
-$1.29 B
|
-$1.26 B
|
-$1.32 B
|
-$1.25 B
|
-$1.38 B
|
-$1.39 B
|
-$1.45 B
|
-$1.35 B
|
| Income Before Tax |
$12.40 B
|
$8.69 B
|
$6.90 B
|
$2.50 B
|
-$265.00 M
|
$3.92 B
|
$1.55 B
|
$1.99 B
|
$2.23 B
|
$3.55 B
|
| Income Before Tax Ratio |
0.21
|
0.16
|
0.15
|
0.06
|
-0.01
|
0.15
|
0.06
|
0.09
|
0.1
|
0.15
|
| Income Tax Expense |
$2.17 B
|
$1.65 B
|
$938.00 M
|
-$792.00 M
|
-$380.00 M
|
$772.00 M
|
$321.00 M
|
-$57.00 M
|
-$641.00 M
|
$146.00 M
|
| Net Income |
$10.26 B
|
$7.04 B
|
$5.96 B
|
$3.29 B
|
$112.00 M
|
$3.20 B
|
$1.34 B
|
$2.16 B
|
$3.00 B
|
$3.50 B
|
| Net Income Ratio |
0.17
|
0.13
|
0.13
|
0.07
|
0
|
0.12
|
0.05
|
0.1
|
0.13
|
0.15
|
| EPS |
3.3 |
1.14 |
1.91 |
1.06 |
0.04 |
1.22 |
0.52 |
0.85 |
1.19 |
1.39 |
| EPS Diluted |
3.27 |
1.13 |
1.91 |
1.06 |
0.04 |
1.22 |
0.52 |
0.85 |
1.19 |
1.38 |
| Weighted Average Shares Out |
$3.10 B
|
$3.10 B
|
$3.12 B
|
$3.10 B
|
$2.84 B
|
$2.62 B
|
$2.60 B
|
$2.53 B
|
$2.53 B
|
$2.53 B
|
| Weighted Average Shares Out Diluted |
$3.12 B
|
$3.13 B
|
$3.12 B
|
$3.12 B
|
$2.85 B
|
$2.63 B
|
$2.60 B
|
$2.53 B
|
$2.53 B
|
$2.53 B
|
| Link |
|
|
|
|
|
|
|
|
|
|
